{"contentid": 488117, "importid": NaN, "name": "Roche cocktail stops coronavirus and key variants", "introduction": "Top-line data from a trial testing an antibody cocktail in non-hospitalized people with the novel coronavirus show a reduction in the risk of hospitalization or death by 70%.", "content": "<p>Top-line data from a trial testing an antibody cocktail in non-hospitalized people with the novel coronavirus show a reduction in the risk of hospitalization or death by 70%.</p>\n<p>The Phase III REGN-COV 2067 study met its primary endpoint, comparing treatment with casirivimab and imdevimab with placebo.</p>\n<p>The trial also met all key secondary endpoints, including the ability to reduce symptom duration from 14 to 10 days.</p>\n<h2>Effective coronavirus treatment</h2>\n<p>Developers Roche (ROG: SIX) and Regeneron (Nasdaq: REGN) have already been granted an Emergency Use Authorization (EUA) by the US Food and Drug Administration to offer the treatment for high-risk patients with confirmed COVID-19.</p>\n<p>The antibody combination has now been shown in clinical trials to be effective both as a therapeutic and as a passive vaccine against the novel coronavirus.</p>\n<p>Importantly, according to guidance from the US FDA, the combination is the only monoclonal antibody treatment to retain potency against key emerging variants.</p>\n<p>The European regulator kicked off a rolling review of the treatment at the start of February, while the US government recently upped its order of the product from 300,000 to 1.5 million doses, at a cost of $2.6 billion.</p>\n<p>Commenting on the latest results, Roche chief medical officer Levi Garraway said: &ldquo;New infections continue to rise globally with over three million reported cases last week, so this investigational antibody cocktail may offer hope as a potential new therapy to high-risk patients - particularly in light of recent evidence showing that casirivimab and imdevimab together retain activity against key emerging variants.&rdquo;</p>\n<p>A companion Phase II trial in low risk symptomatic or asymptomatic non-hospitalized patients showed significant and comparable viral load reductions.</p>\n<p>Detailed results from the trial program will be shared with regulatory authorities and submitted for peer review.</p>\n<p>The firms said they would &ldquo;continue to work with the European Medicines Agency (EMA) and other health authorities across the globe.&rdquo;</p>\n<p>Roche is also testing the combo in the Phase III open label RECOVERY trial of hospitalized patients in the UK, and a Phase III trial for the prevention of COVID-19 in household contacts of infected individuals.</p>", "date": "2021-03-23 10:18:00", "meta_title": NaN, "meta_keywords": "coronavirus, trial, cocktail, antibody, Roche, treatment, variants, risk, testing, Phase, patients, stops, data, Topline, non-hospitalized, show, reduction", "meta_description": "Topline data from a trial testing an antibody cocktail in non-hospitalized people with the novel coronavirus show a reduction in the risk of hospitalisation or ", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 1, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-03-23 09:48:25", "updated": "2021-03-23 10:18:50", "access": NaN, "url": "https://www.thepharmaletter.com/article/roche-cocktail-stops-coronavirus-and-key-variants", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "2020_roche_big.jpg", "image2id": "2020_roche_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Anti-virals, Infectious diseases", "topic_tag": "Coronavirus, Drug Trial, Public health, Research", "geography_tag": "Switzerland, USA", "company_tag": "Regeneron Pharmaceuticals, Roche", "drug_tag": "casirivimab, imdevimab, REGN-COV2", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-03-23 10:18:00"}